Trichothecin Inhibits Cancer-Related Features in Colorectal Cancer Development by Targeting STAT3

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Signal transducer and activator of transcription 3 (STAT3) is a key factor in cancer development and progression.
• The IL-6/STAT3 signaling pathway is implicated in advanced colorectal cancer stages.
• Targeting STAT3 presents a promising therapeutic strategy for cancer treatment.

Purpose of the Study:

• To identify and characterize novel inhibitors of STAT3.
• To evaluate the potential of trichothecin (TCN) as a STAT3 inhibitor for colorectal cancer therapy.

Main Methods:

• In vitro assays were used to assess TCN's effects on STAT3.
• Cell proliferation, cell cycle, apoptosis, colony formation, migration, invasion, and HUVEC tube formation assays were performed.
• TCN's binding to the STAT3 SH2 domain and its impact on STAT3 activation, dimerization, and nuclear translocation were investigated.

Main Results:

• Trichothecin (TCN) was identified as a novel inhibitor that binds to the SH2 domain of STAT3, blocking its activation, dimerization, and nuclear translocation.
• TCN inhibited STAT3 transcriptional activity without affecting STAT1 phosphorylation.
• TCN significantly reduced colorectal cancer cell (HCT 116) growth, induced G0/G1 cell cycle arrest, and promoted apoptosis.
• TCN impaired colony formation, migration, and invasion of HCT 116 cells and abolished HUVEC tube formation in vitro.

Conclusions:

• Trichothecin (TCN) effectively inhibits STAT3 signaling and demonstrates potent anti-cancer effects against colorectal cancer cells in vitro.
• TCN targets multiple cancer-related processes, including proliferation, survival, and metastasis, by inhibiting STAT3.
• TCN represents a promising therapeutic candidate for colorectal cancer, warranting further investigation.